Evidence map›Paper›PMID 39606796›Full record

ArticleClinical and translational medicine2024

The gut microbiota-derived metabolite indole-3-propionic acid enhances leptin sensitivity by targeting STAT3 against diet-induced obesity.

Zhiwei Wang, Shaying Yang, Liangju Liu, Aiqin Mao, Hao Kan, Fan Yu, Xin Ma, Lei Feng, Tingting Zhou

Abstract read
In one paragraph

Article in Clinical and translational medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

29 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Review
  4. Article
  5. Review
  6. Review
  7. Article
  8. Article
  9. ExploringBiomolecules & therapeutics · 2026
    Article
  10. Article
  11. Review
  12. Review
  13. Review
  14. New Horizons in Metabolic Health: Unveiling the Future of Drug Discovery and Development.Endocrine, metabolic & immune disorders drug targets · 2026
    Review
  15. Review
  16. Article
  17. Intestinal-related substances in obesity regulation: A comprehensive review.World journal of gastrointestinal pharmacology and therapeutics · 2025
    Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Zhiwei WangDepartment of Pharmacology, Wuxi School of Medicine, Jiangnan University, Wuxi, China.ORCID 0009-0004-6541-1203
Shaying YangDepartment of Pharmacology, Wuxi School of Medicine, Jiangnan University, Wuxi, China.
Liangju LiuDepartment of Pharmacology, Wuxi School of Medicine, Jiangnan University, Wuxi, China.
Aiqin MaoDepartment of Pharmacology, Wuxi School of Medicine, Jiangnan University, Wuxi, China.
Hao KanDepartment of Pharmacology, Wuxi School of Medicine, Jiangnan University, Wuxi, China.
Fan YuDepartment of Pharmacology, Wuxi School of Medicine, Jiangnan University, Wuxi, China.
Xin MaDepartment of Pharmacology, Wuxi School of Medicine, Jiangnan University, Wuxi, China.
Lei FengDepartment of Pharmacology, Wuxi School of Medicine, Jiangnan University, Wuxi, China.
Tingting ZhouDepartment of Pharmacology, Wuxi School of Medicine, Jiangnan University, Wuxi, China.

Funding

National Natural Science Foundation of China 81622007National Natural Science Foundation of China 82025005National Natural Science Foundation of China 82470455National Natural Science Foundation of China 91939301
6 · The paper itself

Abstract

Obesity is associated with the gut microbiome. Here, we report that gut commensal Clostridia bacteria regulate host energy balance through the tryptophan-derived metabolite indole-3-propionic acid (IPA). IPA acts as an endogenous leptin sensitiser to counteract obesity. Mechanistically, IPA is secreted from the gut into the circulation, and then targets to the STAT3 in the hypothalamic appetite regulation centre, promoting its phosphorylation and nuclear translocation, which enhances the body's response to leptin, and regulates the balance between appetite and energy metabolism. The in vitro pull-down assays involving site-directed mutagenesis demonstrate that Trp623 in the SH2 domain is the key binding site for STAT3-IPA interaction. High-fat diet (HFD), rather than genetic factors, induces excessive secretion of antimicrobial peptides by Paneth cells, inhibiting the growth of Clostridia in the gut and resulting in decreased production of the beneficial metabolite IPA. IPA or Clostridium sporogenes supplement effectively controls weight gain, improves glucose metabolism, and reduces inflammation in DIO mice. IPA fails to achieve such effects in ob/ob mice, while exogenous leptin administration restores the therapeutic effect of IPA. Our study suggests that the IPA-based gut-brain axis regulates host metabolism, and supplementation with microbiome-derived IPA could be a promising intervention strategy for treating obesity.

Indexed as

Diet, High-FatGastrointestinal MicrobiomeIndolesLeptinObesitySTAT3 Transcription FactorAnimalsDisease Models, AnimalMaleMiceMice, Inbred C57BLindolepropionic acidIndolesLeptinSTAT3 Transcription Factorgut microbiomeIPAleptin sensitivitymetabolismobesitySTAT3

Identifiers

PMID39606796
PMCPMC11602751

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.